EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Capital Increase 
Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting 
2021-07-22 / 07:00 
=---------------------------------------------------------------------------------------------------------------------- 
Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting 
Shares being used in part for payments related to AdVita and APR acquisitions 
Acquisitions are part of Relief's transformation into a fully integrated diversified commercial-stage pharmaceutical 
company 
Geneva, Switzerland, July 22, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company 
"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet 
need, reported today that the Company will, on or around July 27, 2021, issue 1,000,000,000 additional registered 
shares out of the authorized share capital approved by the Annual General Meeting on June 18, 2021. The new shares are 
fully subscribed at par value by the Company's wholly owned subsidiary, Relief Therapeutics International SA, and will 
be listed on the SIX Swiss Exchange on or around July 28, 2021. Some of the shares will be used for contractually 
agreed payments to the respective sellers of AdVita Lifescience GmbH ("AdVita") and APR Applied Pharma Research SA (" 
APR"): approximately 140,000,000^[1] shares and 206,786,784 shares, respectively. The remaining new shares will be held 
as treasury shares for possible future financing transactions, acquisitions, general corporate purposes, and the 
settlement of possible future contingent milestone payments to the APR and AdVita sellers. The APR sellers are 
generally subject to a 75-day lock-up period and a subsequent leak-out schedule. 
Jack Weinstein, CFO and Treasurer of Relief, said: "During the course of 2021, we have taken several important steps to 
transform Relief into a multi-product, revenue-generating company. One critical component of that was the recently 
closed acquisition of APR, which brings us a diverse pipeline, including market-stage products, and provides a 
commercial springboard for future Relief product launches. We also are strengthening our intellectual property position 
with our lead candidate, RLF-100(TM) (aviptadil), through the planned acquisition of AdVita. We are also actively 
continuing to look for other opportunities as we build our business." 
The associated listing prospectus will be listed on the SIX Prospectus Office's website and will be made available upon 
request once it has been approved by the SIX Swiss Exchange, which is expected on or around July 27, 2021. 
### 
ABOUT RELIEF 
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in 
human patients or a strong scientific rationale. Relief's lead drug candidate, RLF-100^TM (aviptadil), a synthetic form 
of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory 
deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a 
Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of 
ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate 
(NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. In addition, Relief's acquisition of 
APR Applied Pharma Research brings a diverse pipeline of marketed and development-stage programs. 
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB 
under the symbol RLFTF. For more information, visit www.relieftherapeutics.com. Follow us on LinkedIn. 
CONTACT:                               FOR MEDIA/INVESTOR INQUIRIES: 
RELIEF THERAPEUTICS Holding AG         MC Services AG 
Jack Weinstein                         Anne Hennecke 
Chief Financial Officer and Treasurer  Tel.: +49 (0) 211-529-252-22 
Mail: contact@relieftherapeutics.com   Mail: relief@mc-services.eu Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. ^[1] The exact figure is i.a. dependent on Relief's closing share price on the SIX trading day preceding the closing date of Relief's acquisition of AdVita's outstanding shares. -----------------------------------------------------------------------------------------------------------------------

End of Media Release ----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      RELIEF THERAPEUTICS Holdings AG 
              Avenue de Sécheron 15 
              1202 Genève 
              Switzerland 
E-mail:       contact@relieftherapeutics.com 
Internet:     https://relieftherapeutics.com 
ISIN:         CH0100191136 
Listed:       SIX Swiss Exchange 
EQS News ID:  1220829 
 
End of News   EQS Group News Service 
=------------

1220829 2021-07-22


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1220829&application_name=news

(END) Dow Jones Newswires

July 22, 2021 01:00 ET (05:00 GMT)